DE60215368D1 - Pyranderivate als inhibitoren von ace und nep - Google Patents

Pyranderivate als inhibitoren von ace und nep

Info

Publication number
DE60215368D1
DE60215368D1 DE60215368T DE60215368T DE60215368D1 DE 60215368 D1 DE60215368 D1 DE 60215368D1 DE 60215368 T DE60215368 T DE 60215368T DE 60215368 T DE60215368 T DE 60215368T DE 60215368 D1 DE60215368 D1 DE 60215368D1
Authority
DE
Germany
Prior art keywords
ace
nep
sub
pyranderivates
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60215368T
Other languages
English (en)
Other versions
DE60215368T2 (de
Inventor
Anne Fink
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of DE60215368D1 publication Critical patent/DE60215368D1/de
Application granted granted Critical
Publication of DE60215368T2 publication Critical patent/DE60215368T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Saccharide Compounds (AREA)
DE60215368T 2001-09-21 2002-09-20 Pyranderivate als inhibitoren von ace und nep Expired - Lifetime DE60215368T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32382501P 2001-09-21 2001-09-21
US323825P 2001-09-21
PCT/EP2002/010608 WO2003027091A1 (en) 2001-09-21 2002-09-20 Pyrane derivatives as both ace- and nep- inhibitors

Publications (2)

Publication Number Publication Date
DE60215368D1 true DE60215368D1 (de) 2006-11-23
DE60215368T2 DE60215368T2 (de) 2007-08-16

Family

ID=23260883

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60215368T Expired - Lifetime DE60215368T2 (de) 2001-09-21 2002-09-20 Pyranderivate als inhibitoren von ace und nep

Country Status (12)

Country Link
US (2) US7071169B2 (de)
EP (1) EP1430045B1 (de)
JP (1) JP4263095B2 (de)
CN (1) CN1304415C (de)
AT (1) ATE342261T1 (de)
BR (1) BR0212899A (de)
CA (1) CA2456281A1 (de)
DE (1) DE60215368T2 (de)
ES (1) ES2274106T3 (de)
HK (1) HK1068332A1 (de)
PT (1) PT1430045E (de)
WO (1) WO2003027091A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2274106T3 (es) 2001-09-21 2007-05-16 Novartis Ag Derivados de pirano como inhibidores tanto de ace como de nep.
TW200900399A (en) 2003-10-01 2009-01-01 Speedel Experimenta Ag Organic compounds
FI20040674A0 (fi) * 2004-05-12 2004-05-12 Orion Corp Menetelmä tromboembolisten sairauksien estoon
CA2590278A1 (en) 2004-12-15 2006-06-22 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and hmg coa reductase inhibitors
WO2006087371A1 (en) * 2005-02-18 2006-08-24 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics
US20060205625A1 (en) * 2005-02-18 2006-09-14 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics
TW200722424A (en) 2005-03-31 2007-06-16 Speedel Experimenta Ag Substituted piperidines
EP1897879A3 (de) 2005-03-31 2008-06-11 Speedel Experimenta AG 2,4,5-Substituierte Piperidine als Renin-Inhibitoren
JP3975226B2 (ja) 2006-01-11 2007-09-12 生化学工業株式会社 シクロアルキルカルボニルアミノ酸誘導体及びその製造方法
JP4047365B2 (ja) 2006-01-11 2008-02-13 生化学工業株式会社 シクロアルカンカルボキサミド誘導体及びその製造方法
US8829209B2 (en) 2006-01-11 2014-09-09 Seikagaku Corporation Cycloalkylcarbonylamino acid ester derivative and process for producing the same
EP2190433A2 (de) * 2007-08-22 2010-06-02 Gilead Colorado, Inc. Therapie für diabeteskomplikationen
WO2009127251A1 (en) * 2008-04-16 2009-10-22 Novartis Ag Combinations comprising a renin inhibitor
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04211648A (ja) * 1990-07-27 1992-08-03 Nippon Kayaku Co Ltd ケト酸アミド誘導体
ATE193706T1 (de) 1993-11-16 2000-06-15 Novartis Ag Zyklische aminosäure-derivate mit ace und nep inhibierender aktivität
US5432186A (en) * 1993-11-16 1995-07-11 Ciba-Geigy Corporation Cyclic amino acid derivatives
DE69923676T2 (de) 1998-04-23 2006-01-12 Novartis Ag Bestimmte heteroaryl substituierte thiol inhibitoren von endothelin wechselnden enzymen
HUP0101640A3 (en) * 1998-04-23 2002-10-28 Novartis Ag Certain thoil inhibitors of endothelin-converting enzyme
AU2001254776A1 (en) 2000-04-06 2001-10-23 Novartis Ag Organic compounds
US6777443B2 (en) * 2001-05-15 2004-08-17 Novartis Ag Dipeptide derivatives
ES2274106T3 (es) 2001-09-21 2007-05-16 Novartis Ag Derivados de pirano como inhibidores tanto de ace como de nep.

Also Published As

Publication number Publication date
US20040266698A1 (en) 2004-12-30
HK1068332A1 (en) 2005-04-29
JP4263095B2 (ja) 2009-05-13
JP2005504099A (ja) 2005-02-10
CN1555372A (zh) 2004-12-15
US7071169B2 (en) 2006-07-04
ATE342261T1 (de) 2006-11-15
PT1430045E (pt) 2007-01-31
EP1430045B1 (de) 2006-10-11
CN1304415C (zh) 2007-03-14
DE60215368T2 (de) 2007-08-16
BR0212899A (pt) 2004-11-03
CA2456281A1 (en) 2003-04-03
EP1430045A1 (de) 2004-06-23
ES2274106T3 (es) 2007-05-16
WO2003027091A1 (en) 2003-04-03
US20060194742A1 (en) 2006-08-31

Similar Documents

Publication Publication Date Title
ATE453393T1 (de) Verwendung von pyridylamiden als angiogenesehemmer
ATE450515T1 (de) Anilinopyrimidinderivate als ikk?inhibitoren, und hiermit in zusammenhang stehende zusammensetzungen und verfahren
DE60324544D1 (de) Muskarin antagonisten
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
DK1265606T3 (da) Celleadhæsionsinhibitorer
BRPI0410630A (pt) antagonista de nk1
HUP0000487A2 (hu) Neurokinin antagonistaként alkalmazható szubsztituált oximszármazékok
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
DE60142921D1 (de) Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren
ATE232873T1 (de) Phosphonsaürederivate als ptp-1b-inhibitoren
ATE253545T1 (de) Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren
DE60215368D1 (de) Pyranderivate als inhibitoren von ace und nep
DE60131160D1 (de) Caspase-inhibitoren und ihre verwendungen
ATE527261T1 (de) 7-aryl-3,9-diazabicycloä3.3.1ünon-6-en-derivate und ihre verwendung als renin-inhibitoren zur behandlung von bluthochdruck, herz-kreislauf- erkrankungen und nierenkrankheiten
DE60323765D1 (de) Inhibitoren der 17 beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten
DE60219911D1 (de) Pyrrolidin-2-on derivate als faktor xa inhibitoren
HK1081194A1 (en) 6-amino-1h-indazole compounds as phosphodiesterase4 inhibitors, pharmaceutical compositions compris ing the same, and use thereof
GB0519760D0 (en) Novel compounds
GB0407025D0 (en) Novel compounds
AU2002339158A1 (en) 2-(3-sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as factor xa inhibitors
DE602004025119D1 (de) Neue derivate von 4,4'-dithiobis-(3-aminobutan-1-sulfonaten) und diese enthaltende zusammensetzungen
ES2183500T3 (es) Nuevos compuestos y composiciones farmaceuticas que los contienen.
DE602004010186D1 (de) Diazaspiropiperidinderivate als inhibitoren von glycintransporter 1 und glycintransporter 2
DK1144348T3 (da) LTA4-hydrolaseinhibitorer

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

R082 Change of representative

Ref document number: 1430045

Country of ref document: EP

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN, DE